Cynapsus Teams up with MJFF: Incorporates Wearable Device for Parkinson's Clinical Study

By CIOReview | Thursday, January 14, 2016

TORONTO, NY: Cynapsus Therapeutics and The Michael J. Fox Foundation (MJFF) for Parkinson’s Clinical Research formed a strategic alliance to incorporate wearable device technology and “big data” solution into Cynapsus clinical study of APL-130277. The partnership will work on for the treatment of patients suffering from Parkinson’s disease (PD); with the help of sublingual (under-the-tongue) formulation of apomorphine.

“This strategic alliance with The Michael J. Fox Foundation and the use of technology enabled research solutions builds on our standing collaborative relationship as well as our  individual commitments to change the lives of people with Parkinson’s disease,” said Anthony Giovinazzo, President and CEO, Cynapsus.

This pilot effort highlights on how the clinical studies utilize data approaches to strengthen the revolution in drug development towards the PD disease. Introduced back in August 2014, MJFF is working on enlarging the storage volumes of patient-generated data and gathering insights through algorithms from this data. The project builds on MJFF’s on-going data science association with Intel Corporation for the growth of the platform. The usage of a consumer wearable and an analytics platform, developed by Michael J. Fox Foundation and Intel for use in Parkinson’s disease research, is a remarkable example of interdisciplinary teamwork. Implementation of this wearable technology will be helpful in collecting data for clinical trial which will improvise the treatment by providing better understanding about the drug impact on patients with weak symptoms of this disease.

 “Clinical studies are the most expensive and time-consuming stages of drug development. Data science approaches hold the potential to accelerate the pace of progress by allowing drug developers to objectively gather and analyze unprecedented volumes of data and more quickly reveal insights about a potential new treatment,” commented Todd Sherer, Ph.D., Chief Executive Officer, MJFF.